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Intravascular ultrasoundAbstract Coronary artery disease (CAD) is known to be the main cause of morbidity and
mortality in patients with diabetes mellitus. Although they do not often show typical recognized
symptoms, diabetic patients suffer from more extensive CAD and hence higher incidence of
multi-vessel CAD than in non-diabetic subjects. Literature has given the strength of evidence in
favor of surgical revascularization in diabetic patients with multi-vessel disease. We report the case
of a 61-year old active smoker and diabetic man with atypical symptoms and positive treadmill test.
The coronary angiography revealed a severe three-vessel disease and distal left main involvement
(SYNTAX score = 49). As the patient refused to follow heart team indication to undergo coronary
bypass grafting, a percutaneous coronary intervention was successfully performed with intra-aortic
balloon counterpulsation support and intravascular ultrasound optimization. The mid-term
outcome was good.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
The perceivable link between the coronary artery disease
(CAD) and diabetes mellitus had been known for many years.
The incidence of coronary artery disease (CAD) in diabetics isfour times higher compared to the age-adjusted general popula-
tion.1 Furthermore, CAD is known to be themain cause ofmor-
bidity and mortality in patients with diabetes mellitus (DM).2
Although they do not often show typical recognized symptoms,
diabetic patients suffer from more extensive CAD and hence
higher incidence of multi-vessel CAD than in non-diabetic
subjects.3 Multi-vessel coronary artery disease revasculariza-
tion is commonly performed throughout the world. Among
approximately 700,000 patients who undergo multivessel
coronary revascularization yearly, 25% have diabetes.2,4 For
the last two decades, there has been intense debate between
interventional cardiologists and surgeons regarding the most
effective mode of revascularization in patients with diabetes,
84 M. Boukhris et al.particularly in those with multivessel disease or left main
stenosis,5–8 until the FREEDOM trial gave the strength of
evidence in favor of coronary artery bypass grafting (CABG).9
However, surgical revascularization is not always feasible or
accepted by all the patients. Otherwise, although single-center
observational data had suggested a reduction in mortality and
major complications with the use of an elective intra-aortic
balloon pump (IABP) during high-risk PCI,10,11 the ﬁrst
randomized controlled evaluation of the safety and efﬁcacy of
counterpulsation during high-risk PCI did not conﬁrm these
ﬁndings.12
2. Case report
A 61-year old, active smoker (1 peak per day since 40 years)
with a history of non-insulin dependent DM for 10 years trea-
ted by 2 daily tablets of metformin, sought medical care for
easy fatigue and chest discomfort on physical exertion since
10 years exacerbating since 3 months. Clinical examination
was normal. Blood tests revealed a preserved renal function
preserved (creatinine 0.98 mg/dl and clearance of creatinine
95 ml/mn), a glycosylated hemoglobin of 7.2% and his lipid
proﬁle showed a hypercholesterolemia of 6.9 mmol/l. No
abnormalities were found in baseline12-lead electrocardio-
gram. The treadmill test showed ST depression of 4 mmFigure 1 Coronary angiogram: (A) Left coronary angiogram:
caudal view showing a distal left main stenosis associated with
proximal LAD stenosis and stenosis of the proximal segment of
ﬁrst marginal branch. (B) Right coronary angiogram: cranial view
showing a double tight stenosis of the ﬁrst and the second
segments of RCA.concomitant to the same reported chest discomfort at the
second step and the patient was admitted. Trans-thoracic
echocardiography found a mildly impaired left ventricular
function (ejection fraction 48%) with a moderate global
hypokinesia. A coronary angiography was performed: left
angiogram revealed calciﬁed distal left main stenosis associ-
ated with proximal left anterior descending (LAD) stenosis
and a stenosis of the proximal segment of ﬁrst marginal
branch; while right coronary angiogram showed a double tight
stenosis of the ﬁrst and the second segments of RCA (Fig. 1).
Risk stratiﬁcation was performed: operative risk was low with
an additive EUROSCORE of 2, while a high SYNTAX score
of 49 was found. Although the patient was clearly informed
about the heart team decision to opt for surgical revasculariza-
tion, he refused to undergo CABG; thus the decision to per-
form PCI was taken. A double femoral 7F access was
performed. As considered as high-risk PCI, elective IABP
was employed during the procedure. A 6 French Judkins right
was engaged in RCA ostium and 2 everolimus-eluting stents
(EES) were implanted. Then, a 7 French XB 4 guiding catheter
was placed in the left main coronary artery and two guidewires
were positioned in LAD and ﬁrst marginal. After ﬁrst
marginal and proximal LAD angioplasties, a provisional
T-stenting of left main was performed with the implantation
of one EES. Intravascular ultrasound (IVUS) was employed
to assess the apposition of left main stent and a post-dilation
was required to optimize it. Final angiographic result was
good. Fig. 2 describes the procedure details.
In-hospital stay was uneventful and the patient was
discharged after 48 h with the following treatment: aspirin,
ticagrelor (dual anti-platelet therapy for 1 year), rosuvastatin,
enalapril and atenolol, and addressed to diabetologist for a
better control of DM.
At 3 months, the patient was asymptomatic with a negative
myocardial scintigraphy. An angiographic control is scheduled
after 8 months from the procedure.3. Discussion
Over the past decades, there has been an extraordinary growth
in available modalities for diagnosing and treating CAD. This
has resulted in signiﬁcant decline in the mortality caused by
CAD during this period of time.13,14 Unfortunately, for rea-
sons that are not completely understood, this decline has not
been appreciated to the same degree by diabetic patients.15
The thought that patients with diabetes often have more severe
forms of CAD, gives intuitively the impression that they are
likely to derive greater clinical beneﬁt from CABG than from
PCI. The debate started with the BARI trial which revealed a
survival advantage for the subgroup of patients with diabetes
treated by CABG rather than angioplasty,8 and was conﬁrmed
in the ﬁnal 10-year follow-up with respective survival rates of
58% vs 46% (p= 0.025).16 The publications of the 5-year out-
comes of the SYNTAX Trial17 and the ASCERT registry18
have shown strong evidence that CABG, in comparison with
PCI, provides a strong survival beneﬁt as well as a marked
reduction in myocardial infarction and repeat revasculariza-
tion in patients with intermediate and more severe CAD as
assessed by SYNTAX scores of >22. The FREEDOM trial
randomized 1900 patients with diabetes and multivessel
CAD, already receiving aggressive medical therapy, to CABG
Figure 2 Percutaneous coronary intervention of left main and three-vessel disease. (A) IABP placement; (B) predilation and everolimus
DES implantation in proximal RCA (3.0 · 20); (C) predilation and everolimus DES implantation in second segment of RCA
(2.75 · 16 mm); (D) good ﬁnal angiographic result of RCA stenting; (E) predilation and everolimus DES implantation in proximal
segment of marginal branch (3.0 · 16); (F) predilation and everolimus DES implantation in proximal LAD (3.0 · 18); (G) predilation with
kissing balloon in distal left main lesion; (H) provision stenting of distal left main with everolimus DES implantation (3.5 · 16 mm); (I)
kissing balloon; (J,K) optimization of left main result after IVUS. (L) Good angiographic ﬁnal result in left coronary angiogram.
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ite outcome of death from any cause, non-fatal MI or stroke,
occurred in 26.6% of the PCI group and 18.7% of the CABG
group (p= 0.005). The beneﬁt of CABG was driven by supe-
rior outcomes in both rates of death from any cause (10.6% vs
14.9%; p= 0.049) and myocardial infarction (6.0% vs 13.9%;
p< 0.001), but at the cost of a higher risk of stroke in the
CABG group (5.2% vs 2.4%; p= 0.03).9
Several other studies have supported the use of CABG
rather than PCI in patients with diabetes. In the CARDIa
trial,19 510 diabetic patients with multi-vessel or complex sin-
gle-vessel CAD were randomized to PCI or CABG. At 1 year
of follow-up, the composite rates of death, myocardial infarc-
tion and stroke were 10.5% in the CABG group and 13.0% in
the PCI group; all-cause mortality rates were 3.2% and 3.2%,
respectively, and the rates of death, MI, stroke or repeat revas-
cularization were 11.3% and 19.3%, respectively.
Evidence from prospective registries also supports the use
of CABG rather than PCI in patients with diabetes andmulti-vessel CAD.20 In a large regional database of 7159 con-
secutive patients with diabetes who underwent coronary revas-
cularization in northern New England 2766 (38.6%) were
similar to the patients randomized in the BARI trial. Of this
cohort, 736 underwent PCI and 2030 underwent CABG. After
adjusting for differences in baseline clinical characteristics, PCI
resulted in signiﬁcantly greater mortality than CABG (HR:
1.49; 95% CI: 1.02–2.17; p= 0.037). The mortality risk was
greater with PCI in 1251 patients with 3-vessel disease (HR:
2.02; 95% CI: 1.04–3.91; p= 0.038) than among 1515 patients
with 2-vessel disease (HR: 1.33; 95% CI: 0.84–2.1; p= 0.21).
The strength of evidence in favor of CABG should under-
pin the decision recommendations of the multidisciplinary
Heart Team and can also give considerable reassurance to
patients and their physicians in recommending this as the opti-
mal revascularization technique in patients with diabetes and
multi-vessel CAD who merit intervention and are at low risk
for surgery and receptive to this option. However, CABG is
not always possible in case of high operative risk, extensive
86 M. Boukhris et al.CAD with a bad distal artery bed, or when the patient refused
surgery, as observed in our case; thus, PCI remains despite of
its risk an attractive and sometimes the last option.
IABP has been in clinical use for more than 4 decades,21
largely on the basis of favorable observational data as well
as the beneﬁcial effect of counterpulsation on coronary blood
ﬂow and myocardial oxygen demand.22 The widespread use of
IABP during high-risk PCI, acute myocardial infarction, and
cardiogenic shock23 had been at odds with the paucity of ade-
quately powered randomized controlled trials in these settings.
The Balloon Pump–Assisted Coronary Intervention Study
(BCIS-1)12 evaluated the effect of elective IABP use on the
incidence of major adverse cardiac and cerebrovascular events
(MACCE) in patients with severe ischemic cardiomyopathy
undergoing PCI. Perera et al.12 found that in high-risk PCI,
prophylactic IABP placement did not reduce 28-day MACCE
occurrence. Although patients undergoing IABP placement
experienced fewer procedural complications, rates of access
complications and minor bleeding were higher. However some
issues should be considered. Most important is the deﬁnition
used for high-risk PCI, which was a combination of impaired
left ventricular function (<30%) and complex CAD.
Although this deﬁnition is in line with previously conducted
studies, no generally accepted guideline-based deﬁnition for
high-risk PCI currently exists. Indeed, in our case, although
the left ejection was relatively preserved, the presence of a tight
calciﬁed stenosis of distal left main and three-vessel disease
with a SYNTAX score of 49 make us consider the procedure
as high-risk PCI. Actually, IABP has class IIb recommenda-
tion (level of evidence C) in the current American College of
Cardiology Foundation/American Heart Association/Society
for Cardiovascular Angiography and Interventions guidelines
for PCI and is only recommended in the presence of hemody-
namic impairment in the current European Society of
Cardiology guidelines on revascularization.24,25 However,
long-term follow-up of BCIS-1 (median 51 months) showed
34% relative reduction in all-cause mortality compared with
unsupported PCI.26
The use of IVUS in left main intervention is able to evaluate
stent underexpansion, incomplete lesion coverage, small stent
area, large residual plaque, and stent malapposition which
have been found to predict stent thrombosis after drug eluting
stent placement.27,28 In the MAIN-COMPARE registry, Park
et al. showed that elective stenting with IVUS guidance,
especially in the placement of drug-eluting stent, may reduce
the long-term mortality rate for unprotected left main coro-
nary artery stenosis when compared with conventional angiog-
raphy guidance. Moreover, de la Torre Hernandez et al.
showed an association of IVUS guidance during PCI with
better outcomes in patients with left main disease undergoing
revascularization with DES.29 Indeed, IVUS-guided procedure
was identiﬁed as a protective predictor for major adverse
events in the overall population (hazard ratio = 0.70) and
the distal unprotected left main subgroup (HR= 0.54).29 In
addition, IVUS may also play a role in the selection of the
most appropriate stenting technique and the eventual need
for a second stent after provisional stenting.30
Finally, in addition to the use of hemodynamic support
and IVUS guidance optimization, the good outcome of our
patient might be due to the relatively preserved ventricular
function.4. Conclusion
According to FREEDOM study, in patients with diabetes and
advanced CAD, CABG was superior to PCI reducing rates of
death and myocardial infarction. However, because of
patients’ preference, high operative risk or anatomical reasons,
surgery cannot be performed; thus PCI with drug-eluting
stents remains a reliable alternative in experienced hands. A
hemodynamic support by IABP and IVUS use might be sup-
plementary tools to optimize the outcome.
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